Associate Professor of Cardiac Electrophysiology
Vanderbilt University Medical Center
Christopher R. Ellis, MD, FACC, FHRS graduated University of Rochester, NY in 2000 and Medicine-Pediatrics residency and Cardiovascular Medicine Fellowship at Vanderbilt University Medical Center 2008. Dr. Ellis completed Cardiac Electrophysiology Fellowship at University of Michigan and joined Vanderbilt in July 2009. He is currently Associate Professor of Medicine and Director of the LAA Closure Program.
His current academic focus within Atrial Fibrillation (AF) has turned to the role of the Left Atrial Appendage (LAA) in AF related stroke, and treatment options to reduce dependence on oral anti-coagulation for stroke risk reduction. With a broad experience performing over > 1000 LAAC cases, Dr. Ellis has helped advance LAA therapy as the top worldwide implanter for the Amulet IDE trial, executive committee guidance for LARIAT and the AMAZE trial, top enrolling physician for the AMAZE trial, and as principle investigator for numerous physician initiated prospective clinical trials. He published the first series of Watchman LAAC following incomplete surgical LAA ligation in 2018, the first independent evaluation of the angiographic efficacy of the Atriclip system placed by thoracoscopic approach, setting the basis for the prospective Atriclip stroke trial. Recent work has identified small LAAC peri-device leaks (PDL 1-5mm) associated with increased risk of stroke and progression over time, as well as DRT mechanism and prevention strategies. He is currently involved in early feasibility of the CONFORMAL device, and actively enrolling in CATALYST, OPTION, AMAZE-CAP, and CHAMPION trials.
Disclosure information not submitted.